Cidara Therapeutics Revenue 2014-2022 | CDTX
Cidara Therapeutics revenue from 2014 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Cidara Therapeutics Annual Revenue (Millions of US $) |
2021 |
$50 |
2020 |
$12 |
2019 |
$21 |
2018 |
$ |
2017 |
$ |
2016 |
$ |
2015 |
$ |
2014 |
$ |
2013 |
$ |
Cidara Therapeutics Quarterly Revenue (Millions of US $) |
2022-09-30 |
$41 |
2022-06-30 |
$6 |
2022-03-31 |
$7 |
2021-12-31 |
$7 |
2021-09-30 |
$7 |
2021-06-30 |
$33 |
2021-03-31 |
$2 |
2020-12-31 |
$4 |
2020-09-30 |
$2 |
2020-06-30 |
$3 |
2020-03-31 |
$3 |
2019-12-31 |
$2 |
2019-09-30 |
$19 |
2019-06-30 |
|
2019-03-31 |
|
2018-12-31 |
|
2018-09-30 |
|
2018-06-30 |
|
2018-03-31 |
|
2017-12-31 |
|
2017-09-30 |
|
2017-06-30 |
|
2017-03-31 |
|
2016-12-31 |
|
2016-09-30 |
|
2016-06-30 |
|
2016-03-31 |
|
2015-12-31 |
|
2015-09-30 |
|
2015-06-30 |
|
2015-03-31 |
|
2014-12-31 |
|
2014-09-30 |
|
2014-06-30 |
|
2014-03-31 |
|
2013-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.087B |
$0.050B |
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
|